Uncategorized

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space dominated by Vertex.

CEO Scott Whitaker said “an exemption was provided for most medical devices during President Trump’s first term with respect to the tariffs on China, and we are advocating for a similar approach.”

340B Health and two safety-net hospitals want to help the government prove that drugmakers are required to give upfront discounts on 340B drugs.

Prospect Medical Holdings said Friday it has a deal to sell Crozer Health to a consortium of nonprofit healthcare operators. However, the system offered few specifics about deal terms.

Brent Shafer, Baxter’s lead independent director, will serve as interim CEO. The company also promoted Heather Knight to chief operating officer.

Tariffs and price inflation for specialty medications will increase costs, according to research from Vizient. 

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks after J&J secured FDA monotherapy approval for its esketamine nasal spray Spravato in the same indication.

APAC offers stability in an increasing challenging global geopolitical environment for clinical stage drug development.

J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, according to analysts.

Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the way for its full approval for the treatment of certain colorectal cancers, according to the company.